News
14h
Axios on MSNA new AI threat-hunting startup has emerged from stealth with backing from Bain Capital Ventures, In-Q-TelA new startup offering an AI-enabled threat-hunting platform is emerging from stealth today with backing from Bain Capital ...
Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...
Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...
Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...
US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...
Bristol Myers Squibb (NYSE:BMY) and Bain Capital have announced the establishment of a new independent biopharmaceutical ...
Explore more
The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...
19h
Pharmaceutical Technology on MSNBMS and Bain Capital forge $300m immunology spinoffThe biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.
BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...
We recently compiled a list of 11 Best Undervalued Stocks to Invest in Now. Lincoln National Corporation stands third on our ...
Back in May, Bain and Botanic spent $26 million to acquire the property from Fujifilm Recording Media. The 15-acre site will ...
The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results